(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083376 A3

(51) International Patent Classification[7]: A61K 38/04, C12N 9/12

(21) International Application Number: PCT/SG2004/000063

(22) International Filing Date: 19 March 2004 (19.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0306575.2 21 March 2003 (21.03.2003) GB

(71) Applicant *(for all designated States except US)*: **INSTITUTE OF MOLECULAR AND CELL BIOLOGY** [SG/SG]; 30 Medical Drive, Singapore 117609 (SG).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **LIM, Louis** [MY/SG]; BMRC, 20 Biopolis Way, #07-01 Centros, Singapore 138668 (SG). **AHMED, Sohail** [GB/SG]; Institute of Molecular and Cell Biology, Annexe 3-93, 30 Medical Drive, Singapore 117609 (SG). **KOZMA, Robert** [GB/SG]; Exploit Technologies Pte, Ltd, 30 Biopolis Street, #09-02 Matrix, Singapore 138671 (SG).

(74) Agent: **AXIS INTELLECTUAL CAPITAL PTE LTD.**; 21A Duxton Road, Singapore 089487 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: MODULATORS



(57) Abstract: We disclose an isoform specific antagonist of PAK kinase, which is preferably a molecule capable of modulating an interaction between Nck and a PAK isoform. In particular αPAK, βPAK and γPAK specific inhibitors are disclosed. We also disclose methods of treatment of diseases preferably characterised by a defect in nerve regeneration, comprising modulating an activity of a PAK kinase isoform, preferably αPAK kinase or γPAK kinase, or both.

WO 2004/083376 A3

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
18 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.